- Home
- ULCC vs RCUS Comparison
ULCC vs RCUS Comparison
Compare ULCC & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ULCC
- RCUS
- Stock Information
- Founded
- ULCC 1994
- RCUS 2015
- Country
- ULCC United States
- RCUS United States
- Employees
- ULCC N/A
- RCUS N/A
- Industry
- ULCC Air Freight/Delivery Services
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- ULCC Consumer Discretionary
- RCUS Health Care
- Exchange
- ULCC Nasdaq
- RCUS Nasdaq
- Market Cap
- ULCC 719.5M
- RCUS 727.1M
- IPO Year
- ULCC 2021
- RCUS 2018
- Fundamental
- Price
- ULCC $3.88
- RCUS $8.28
- Analyst Decision
- ULCC Hold
- RCUS Buy
- Analyst Count
- ULCC 11
- RCUS 11
- Target Price
- ULCC $5.67
- RCUS $25.33
- AVG Volume (30 Days)
- ULCC 4.8M
- RCUS 1.2M
- Earning Date
- ULCC 05-01-2025
- RCUS 05-06-2025
- Dividend Yield
- ULCC N/A
- RCUS N/A
- EPS Growth
- ULCC N/A
- RCUS N/A
- EPS
- ULCC 0.30
- RCUS N/A
- Revenue
- ULCC $3,822,000,000.00
- RCUS $141,000,000.00
- Revenue This Year
- ULCC $9.75
- RCUS N/A
- Revenue Next Year
- ULCC $12.72
- RCUS $25.77
- P/E Ratio
- ULCC $13.01
- RCUS N/A
- Revenue Growth
- ULCC 5.99
- RCUS N/A
- 52 Week Low
- ULCC $2.79
- RCUS $6.50
- 52 Week High
- ULCC $10.26
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- ULCC 53.27
- RCUS 48.63
- Support Level
- ULCC $2.97
- RCUS $7.06
- Resistance Level
- ULCC $3.68
- RCUS $9.35
- Average True Range (ATR)
- ULCC 0.25
- RCUS 0.55
- MACD
- ULCC 0.18
- RCUS 0.06
- Stochastic Oscillator
- ULCC 96.58
- RCUS 53.28
About ULCC Frontier Group Holdings Inc.
Frontier Group Holdings Inc is an ultra-low-cost carrier whose business is focused on Low Fares Done Right. The company owns a fleet of 120 Airbus single-aisle aircraft, consisting of 13 A320ceos, 82 A320neos, 21 A321ceos and 4 A321neos. The use of these aircraft, their seating configuration, weight-saving tactics, and baggage process have all contributed to the ability to continue to be the fuel-efficient of all the U.S. The Company is managed as a single business unit that provides air transportation for passengers. Majority of revenue is from Domestic flight follow by International.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.